| Patents for C07K 7 - Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof (42,273) |
|---|
| 01/10/2007 | EP1417227B1 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/10/2007 | CN1894281A Treatment of viral infections |
| 01/10/2007 | CN1894278A Akt activity specifically inhibiting polypeptide |
| 01/10/2007 | CN1894277A Periodic antimicrobial peptides |
| 01/10/2007 | CN1894273A Peptide inhibiting angiotensin converting enzyme |
| 01/10/2007 | CN1894272A 蛋白质表达 Protein expression |
| 01/10/2007 | CN1893967A Leukocyte internalized peptide-drug conjugates |
| 01/10/2007 | CN1891712A Method for designing and preparing small peptide high containing branched chain amino acids |
| 01/10/2007 | CN1294418C Method and reagent box for inspecting mycelian protein antibody of white candida |
| 01/10/2007 | CN1294259C Production process of subtilin surfactant |
| 01/10/2007 | CN1294148C Single-stranded cyctic trispecific antibody |
| 01/10/2007 | CN1294146C Polypeptide combined with T cell surface co-stimulation molecule CD137 and its use |
| 01/09/2007 | US7160983 1((-4-oxo- N2-(12-methyl-1-oxotetradecyl) L-ornithine) 4-(4-(4- hydroxyphenyl)-L-threonine)-5-L-serine-echinocandin B, and other derivatives |
| 01/09/2007 | US7160982 Peptide substrate identified by type BoNT/B botulinus toxin and use thereof for assaying and/or detecting said toxin or corresponding inhibitors |
| 01/09/2007 | US7160863 Fusion protein contains amino acid sequence with 9 to 13 residues of arginine; antagonist of Nuclear Factor Activated T cell (NFAT); short effectiveness and no side effects or antigenicity; signal sequence, immunosuppressants, biodrugs |
| 01/09/2007 | US7160856 Such as alpha-O-linked glycopeptides with clustered glycodomains which are useful as anticancer agents |
| 01/09/2007 | US7160685 Peptides having SEQ ID NO: 2 with immunogenic epitopes activating CD8+ class I major histocompatibility complex restricted cytotoxic T-lymphocytes for patients harboring latent HCMV infection in the absence of active viral replication; using enriched antigen presenting cells; vaccines |
| 01/09/2007 | CA2286190C Gnrh antagonists being modified in positions 5 and 6 |
| 01/09/2007 | CA2232325C Tumor rejection antigens presented by hla-b44 molecules, and uses thereof |
| 01/09/2007 | CA2194352C Diagnostic methods and compositions relating to the proteoglycan proteins of cartilage breakdown |
| 01/09/2007 | CA2168268C Aids and sle prophylactics |
| 01/04/2007 | WO2007001335A2 Ramoplanin derivatives possessing antibacterial activity |
| 01/04/2007 | WO2007000979A1 Self-assembling peptide and gel produced from the same |
| 01/04/2007 | WO2007000770A2 Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes |
| 01/04/2007 | WO2007000036A2 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| 01/04/2007 | WO2006019982A3 Pin1-modulating compounds and methods of use thereof |
| 01/04/2007 | US20070004904 G-csf conjugates |
| 01/04/2007 | US20070004637 Alzheimer's disease; for promoting secretion of amyloid precursor protein-alpha (sAPP), neurodegenerative disease, neuropathy in cerebrovascular disease, head trauma, spinal damage, encephalitis sequela, or cerebral palsy, memory disorder |
| 01/04/2007 | US20070004636 Method of degrading transcriptional factors of saccharometabolism-associated gene, method for inhibiting the degradation, and agent for inhibiting degradation and degradation inhibitor |
| 01/04/2007 | US20070004633 Administering a peptide containing Gly-His-Lys conjugated to an alkanoic acid, lipoic acid or its reduced form, dihydrolipoic acid, N-lipoyllysine or retinoic acid to stimulate hair growth or stop hair loss; may be mixed with a sunscreen |
| 01/04/2007 | US20070004632 An isolated BAX gene frameshift-mutation polypeptide is used to stimulate the proliferation of human T cells, T cellular immunity; for treating cancer patient; cancer vaccines |
| 01/04/2007 | US20070004631 Method for synthesis of phospholipids-PEG-biomolecule conjugates |
| 01/04/2007 | US20070004007 Peptide consisting tumor necrosis factor alpha converting enzyme protease inhibitor; growth hormone related disease; Alzheimer's disease; used to induce apoptosis of cancer cells |
| 01/04/2007 | US20070003982 Analyzing nerve cell damage |
| 01/04/2007 | US20070003974 Cene-E biopolymer marker indicative of age matched control |
| 01/04/2007 | US20070003569 Recombinant polypeptides, which can be used as purified antigens for the detection and control of tuberculosis |
| 01/04/2007 | CA2613193A1 Thrombospondin-1 derived peptides and treatment methods |
| 01/04/2007 | CA2613126A1 Use of mas g-protein-coupled receptor agonists and antagonists as apoptotic activity modulators for prevention and treatment of diseases |
| 01/03/2007 | EP1737961A1 Modified bouganin proteins, cytotoxins and methods and uses thereof |
| 01/03/2007 | EP1737884A1 Alpha helical mimics, their uses and methods for their production |
| 01/03/2007 | EP1737883A2 Synthetic peptides containing the motif "ywwlxp" as anthrax toxin antidotes |
| 01/03/2007 | EP1737882A1 Peptide inhibitors of metalloproteinase activity |
| 01/03/2007 | EP1737483A2 Cell death modulation via antagonists of fasl and fas activation |
| 01/03/2007 | EP1737481A2 Peptides of il1 beta and tnf alpha and method of treatment using same |
| 01/03/2007 | EP1625150B1 Tripeptides and derivatives thereof for cosmetic application in order to improve skin structure |
| 01/03/2007 | EP1578928A4 Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
| 01/03/2007 | EP1539804B1 Synthesis and characterization of novel systems for guidance and vectorization of molecules of therapeutic interest towards target cells |
| 01/03/2007 | EP1511765B1 Par-2-activating peptide derivative and pharmaceutical composition using the same |
| 01/03/2007 | EP1430075B1 Antibacterial macrocycles |
| 01/03/2007 | EP1390403B1 Peptides derived from neural thread proteins and their medical use |
| 01/03/2007 | EP1337551B1 Substance p analogs for the treatment of cancer |
| 01/03/2007 | EP1334124B1 Diastereomeric peptides and pharmaceutical compositions comprising them |
| 01/03/2007 | EP1278534B1 Methods and compositions for impairing multiplication of hiv-1 |
| 01/03/2007 | EP1073675B1 A process for the conversion of echinocandin class of peptides to their c4-homotyrosine monodeoxy analogues |
| 01/03/2007 | EP0787139B1 Synthetic peptides and vaccines comprising same |
| 01/03/2007 | EP0771213B1 Haemophilus influenzae adherence and penetration proteins |
| 01/03/2007 | CN1890215A Inhibitors of hepatitis c virus ns3/ns4a serine protease |
| 01/03/2007 | CN1887902A Amino acid short peptide chelate and its prepn |
| 01/03/2007 | CN1887901A Human tumor M2-type pyruvate kinase antigen determinant polypeptide and antibody and their application in diagnositic kit |
| 01/03/2007 | CN1887829A Synthesis process of 18F lebeled positive electron radioactive tracer with ionic liquid as phase transfer catalyst |
| 01/03/2007 | CN1293096C Method for synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide |
| 01/03/2007 | CN1293092C Method for separating lacti-streptocin from fermentation liquid of lacti-galactococcus |
| 01/03/2007 | CN1292796C Controlled release composition and method of producing the same |
| 01/02/2007 | US7158891 Method and system to build optimal models of 3-dimensional molecular structures |
| 01/02/2007 | US7157423 Using fumaric acid mono- and diamides, or monoamido fumaric acid monoesters for therapy of an autoimmune disease; transplantation medicine; therapy of mitochondrial diseases, for therapy of NF-kappaB mediated diseases |
| 01/02/2007 | US7157422 Glycogen synthase kinase-3 inhibitors |
| 01/02/2007 | US7157420 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 01/02/2007 | US7157419 Growth factor binding molecules |
| 01/02/2007 | US7157275 growing adherent cells using a cell adhesion promoting ("CAP") peptide covalently coupled to a cell adhesion resistant layer such as hyaluronic acid on a polystyrene surface to promote cell attachment, growth differentiation, in culture; biological scaffolds |
| 01/02/2007 | US7157225 Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens |
| 01/02/2007 | US7157091 Endosomal targeting signal contains an endosomal targeting portion of human invariant chain Ii or LAMP-1. |
| 01/02/2007 | CA2295219C Integrin binding peptide and use thereof |
| 01/02/2007 | CA2162468C Use of nona- and decapeptides in the preparation of a drug for the treatment of aids |
| 12/28/2006 | WO2006138721A1 Anti-gfralpha3 antibodies |
| 12/28/2006 | WO2006136892A2 Novel cherkasky fusion proteins containing antibody binding proteins or the regions thereof |
| 12/28/2006 | WO2006099480A3 Stress proteins and peptides and methods of use thereof |
| 12/28/2006 | WO2006023452A3 Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases |
| 12/28/2006 | US20060293372 Beta-sheet mimetics and methods relating to the use thereof |
| 12/28/2006 | US20060293247 Peptide derivatives; thyrotropin-releasing hormone-degrading; brain and spinal injuries, central nervous system disorders |
| 12/28/2006 | US20060293245 P21 derived peptides and uses thereof |
| 12/28/2006 | US20060293244 Anti-inflammatory compounds and uses thereof |
| 12/28/2006 | US20060293242 Transporting of taxoid derivatives through the blood brain barrier |
| 12/28/2006 | US20060292657 Phex substrates and methods using same |
| 12/28/2006 | US20060292648 Screening for target that disrupts interaction between human osteopontin (OPN) and an alpha 4 integrin; inflammatory diseases |
| 12/28/2006 | US20060292644 Novel tumor-associated marker |
| 12/28/2006 | US20060292613 Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions |
| 12/28/2006 | US20060292078 Optical imaging of colorectal cancer |
| 12/28/2006 | US20060292075 Labelled glutamine and lysine analogues |
| 12/28/2006 | CA2612522A1 Lkktet and/or lkktnt peptide compositions and methods |
| 12/28/2006 | CA2612417A1 Anti-gfralpha3 antibodies |
| 12/28/2006 | CA2608278A1 Immunogenic compositions for chlamydia trachomatis |
| 12/27/2006 | EP1736480A1 Artificial protein, method for absolute quantification of proteins and uses thereof |
| 12/27/2006 | EP1735434A1 Method for modification of nmda receptors through inhibition of src |
| 12/27/2006 | EP1735345A2 Processes for preparing eptifibatide and pertinent intermediate compounds |
| 12/27/2006 | EP1735336A2 Omi pdz modulators |
| 12/27/2006 | EP1735335A1 Cell-killing peptide |
| 12/27/2006 | EP1734971A1 Polymer-based sustained release device |
| 12/27/2006 | EP1480961B1 Glutaminyl based dpiv inhibitors |
| 12/27/2006 | EP1404704B1 Bridged bicyclic serine protease inhibitors |
| 12/27/2006 | EP1105505B1 Compound and method for the prevention and/or the treatment of allergy |